Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Neoplasms 165Breast Neoplasms 163Carcinoma, Non-Small-Cell Lung 143Colorectal Neoplasms 101Prostatic Neoplasms 99Lung Neoplasms 86Ovarian Neoplasms 78Neoplasm Metastasis 72Multiple Myeloma 71Pancreatic Neoplasms 67Leukemia, Myeloid, Acute 59Endometrial Neoplasms 47Squamous Cell Carcinoma of Head and Neck 44Lymphoma 42Stomach Neoplasms 41Recurrence 40Melanoma 39Glioblastoma 39Carcinoma, Renal Cell 39Brain Neoplasms 39Carcinoma, Hepatocellular 38Urinary Bladder Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 37Lymphoma, Non-Hodgkin 34Leukemia, Lymphocytic, Chronic, B-Cell 34Hematologic Neoplasms 34Glioma 34Sarcoma 33Esophageal Neoplasms 31Small Cell Lung Carcinoma 30

Interventions

enzalutamide 1darolutamide 1cabazitaxel 1apalutamide 1Prednisone 1Docetaxel 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Metastatic Castration-resistant Prostate Neoplasms × 30 days × Clear all
NCT05818683 2026-06-05

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Janssen Research & Development, LLC

Phase 1 Recruiting
300 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Neoplasms

NCT07164443 2026-06-05

KLK2-comPAS

Janssen Research & Development, LLC

Phase 3 Recruiting
663 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡